Drugs / ZSTK474
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01682473 | Sep 2012 → Apr 2015 | neoplasm | Zenyaku Kogyo Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01280487 | Jan 2011 → Dec 2013 | neoplasm | Zenyaku Kogyo Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZSTK474 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01280487 ↗ |
| Known as | TCMDC-137004 | ChEMBL registry synonym — accepted as the source's own label CHEMBL586702 ↗ |
| Action | Inhibit | “an oral phosphatidylinositol 3-kinase (PI3K) inhibitor” NCT01280487 ↗ |
| Modality | Small molecule | — CHEMBL586702 ↗ |
| Route | Oral | “Daily oral dosing for 21 days each cycle” NCT01280487 ↗ |